drugset / Trial / NCT00488761

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

NCT00488761

Phase 4 Completed 50 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

Tigecycline's activity against resistant organisms, as well as significant coverage of both gram-positive and gram-negative bacteria, may provide a valuable therapeutic alternative in treating patients with complicated skin and/or skin structure infections.

Timeline

Start
2006-07
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigecycline Small molecule

Indications